Librada Fortuna

Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial

Punnee Pitisuttithum, Kulkanya Chokephaibulkit, Chukiat Sirivichayakul et al. · The Lancet Infectious Diseases · 2018 · 39 citations

Veterinary Medicine, Immunology, Pediatrics +13

Failure to thrive: Case definition & guidelines for data collection, analysis, and presentation of maternal immunisation safety data

Elizabeth Ross, Flor M. Muñoz, Bassey E. Edem et al. · Vaccine · 2017 · 23 citations · Full text

Medicine, Immunology, Maternal Health +16

Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines

Punnee Pitisuttithum, Jittima Dhitavat, Chukiat Sirivichayakul et al. · EClinicalMedicine · 2021 · 23 citations · Full text

Medicine, Immunology, Pediatrics +17

Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand

Librada Fortuna, Surasith Chaithongwongwatthana, Ngamphol Soonthornworasiri et al. · Vaccine · 2020 · 17 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17

A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age

Kulkanya Chokephaibulkit, Thanyawee Puthanakit, Niranjan Bhat et al. · Vaccine · 2021 · 14 citations · Full text

Veterinary Medicine, Maternal Health, Obstetrics +17